Profits at Irish J&J subsidiary doubled in 2021 Pre-tax profits at an Irish subsidiary of Covid-19 vaccine producer, Johnson & Johnson, almost doubled to €540.97m in 2021. Business • 20 Mar 23
Profits at Irish J&J subsidiary doubled in 2021 Pre-tax profits at an Irish subsidiary of Covid-19 vaccine producer, Johnson & Johnson, almost doubled to €540.97m in 2021. Business • 20 Mar 23
Horizon Therapeutics in sale talks with three firms Horizon Therapeutics has said its board is engaged in highly preliminary discussions with three pharmaceutical giants for potential takeover offers, sending its shares surging 31% in extended trading after the US markets closed last night. Business • 30 Nov 22
Horizon Therapeutics in sale talks with three firms Horizon Therapeutics has said its board is engaged in highly preliminary discussions with three pharmaceutical giants for potential takeover offers, sending its shares surging 31% in extended trading after the US markets closed last night. Business • 30 Nov 22
J&J beats on earnings but warns of potential job cuts Johnson & Johnson has posted better than expected third-quarter earnings on strong demand for its cancer drug Darzalex, but said it may still cut some jobs as it contends with inflationary pressure and challenges created by the strong dollar. Business • 18 Oct 22
J&J beats on earnings but warns of potential job cuts Johnson & Johnson has posted better than expected third-quarter earnings on strong demand for its cancer drug Darzalex, but said it may still cut some jobs as it contends with inflationary pressure and challenges created by the strong dollar. Business • 18 Oct 22
J&J results beat estimates on strong pharma unit Johnson & Johnson reported quarterly results that beat analysts' estimates on strength at its pharmaceuticals unit, even as the company cut its full-year adjusted profit forecast due to a stronger dollar. Business • 19 Jul 22
J&J results beat estimates on strong pharma unit Johnson & Johnson reported quarterly results that beat analysts' estimates on strength at its pharmaceuticals unit, even as the company cut its full-year adjusted profit forecast due to a stronger dollar. Business • 19 Jul 22
Cerenovus to invest €50m in Galway site €50m is to be invested by neurovascular care company Cerenovus in its plant in Galway. Business • 14 Feb 22
Cerenovus to invest €50m in Galway site €50m is to be invested by neurovascular care company Cerenovus in its plant in Galway. Business • 14 Feb 22
Johnson & Johnson ordered to pay $572m in opioids trial A US judge found Johnson & Johnson liable for fueling an opioid epidemic in Oklahoma by deceptively marketing painkillers and ordered the company to pay damages of $572 million. World • 27 Aug 19
Johnson & Johnson ordered to pay $572m in opioids trial A US judge found Johnson & Johnson liable for fueling an opioid epidemic in Oklahoma by deceptively marketing painkillers and ordered the company to pay damages of $572 million. World • 27 Aug 19
Johnson & Johnson to pay $55m in talc-powder trial Johnson & Johnson has been ordered by a US jury to pay $55m (€47m) to a woman who said that using the company’s talc-powder products for feminine hygiene caused her to develop ovarian cancer. News • 03 May 16
Johnson & Johnson to pay $55m in talc-powder trial Johnson & Johnson has been ordered by a US jury to pay $55m (€47m) to a woman who said that using the company’s talc-powder products for feminine hygiene caused her to develop ovarian cancer. News • 03 May 16
Johnson & Johnson knew of cancer risk, says lawyer A lawyer for the family of a woman whose death from ovarian cancer was linked to her use of Johnson & Johnson talc-based Baby Powder and Shower to Shower said company documents show using the products could cause the disease. News • 25 Feb 16
Johnson & Johnson knew of cancer risk, says lawyer A lawyer for the family of a woman whose death from ovarian cancer was linked to her use of Johnson & Johnson talc-based Baby Powder and Shower to Shower said company documents show using the products could cause the disease. News • 25 Feb 16
J&J plans $1.75bn Alios acquisition Johnson & Johnson plans to acquire Alios BioPharma, a private company specializing in treatments for viral diseases, for $1.75 billion, the companies have announced. Business • 30 Sep 14
J&J plans $1.75bn Alios acquisition Johnson & Johnson plans to acquire Alios BioPharma, a private company specializing in treatments for viral diseases, for $1.75 billion, the companies have announced. Business • 30 Sep 14
Pfizer, J&J scrap Alzheimer's study as drug fails Pfizer and Johnson & Johnson have decided to scrap further studies of one of the most anticipated experimental drugs for Alzheimer's disease. Business • 07 Aug 12
Pfizer, J&J scrap Alzheimer's study as drug fails Pfizer and Johnson & Johnson have decided to scrap further studies of one of the most anticipated experimental drugs for Alzheimer's disease. Business • 07 Aug 12
